
Telephone Conference Memorandum - 8/3/2007 - AFLURIA


 
 
TELEPHONE CONFERENCE MEMORANDUM

 


STN 125254/0:

CTD BLA for Influenza Virus Vaccine

 


SPONSOR:

CSL Limited

 


PRODUCT:

Influenza Virus Vaccine

 


DATE:

August 3, 2007

 

CBER REPRESENTATIVE:
 Katherine Berkhousen
 Rakesh Pandey

CSL REPRESENTATIVE:
 Paul Hartman
 Tel: 610-878-4644

SUMMARY:

CSL contacted to discuss the following CMC concerns:
1.--------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 ---------------------------------------------------------------
2.--------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 ------------------------
3.--------------------------------------------------------------------------------------------------------------------------------------
 -------------------------------------------------------------------------------------------------------------------------------

 
